Does the media refer more to BCRX or LXRX?

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 5 mentions for Lexicon Pharmaceuticals and 4 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.91 beat Lexicon Pharmaceuticals' score of 0.46 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to INVA or LXRX?

In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for Lexicon Pharmaceuticals and 3 mentions for Innoviva. Innoviva's average media sentiment score of 0.78 beat Lexicon Pharmaceuticals' score of 0.46 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NVAX or LXRX?

In the previous week, Novavax had 13 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 18 mentions for Novavax and 5 mentions for Lexicon Pharmaceuticals. Novavax's average media sentiment score of 0.61 beat Lexicon Pharmaceuticals' score of 0.46 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ZBIO or LXRX?

In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 5 mentions for Lexicon Pharmaceuticals and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.62 beat Lexicon Pharmaceuticals' score of 0.46 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Lexicon Pharmaceuticals (LXRX) Competitors

$2.19 -0.02 (-0.68%)

As of 01:13 PM Eastern

Compare

LXRX vs. CLDX, BCRX, INVA, NVAX, and ZBIO

Should you buy Lexicon Pharmaceuticals stock or one of its competitors? MarketBeat compares Lexicon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lexicon Pharmaceuticals presently has a consensus price target of $4.55, indicating a potential upside of 107.29%. Celldex Therapeutics has a consensus price target of $49.78, indicating a potential upside of 57.65%. Given Lexicon Pharmaceuticals' higher possible upside, research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Lexicon Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	19.58	-$50.34M	-$0.07	N/A
Celldex Therapeutics	$1.54M	1,609.30	-$258.76M	-$4.26	N/A

In the previous week, Lexicon Pharmaceuticals had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Lexicon Pharmaceuticals and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.87 beat Lexicon Pharmaceuticals' score of 0.46 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lexicon Pharmaceuticals	Neutral
Celldex Therapeutics	Very Positive

Celldex Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Lexicon Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Summary

Lexicon Pharmaceuticals beats Celldex Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Lexicon Pharmaceuticals has a net margin of -37.46% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Lexicon Pharmaceuticals' return on equity of -18.64% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

BioCryst Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$885.72M	2.55	$263.86M	-$1.78	N/A
Lexicon Pharmaceuticals	$49.80M	19.58	-$50.34M	-$0.07	N/A

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 5 mentions for Lexicon Pharmaceuticals and 4 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.91 beat Lexicon Pharmaceuticals' score of 0.46 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals currently has a consensus price target of $20.70, indicating a potential upside of 132.98%. Lexicon Pharmaceuticals has a consensus price target of $4.55, indicating a potential upside of 107.29%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Summary

BioCryst Pharmaceuticals beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Innoviva?

Innoviva (NASDAQ:INVA) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for Lexicon Pharmaceuticals and 3 mentions for Innoviva. Innoviva's average media sentiment score of 0.78 beat Lexicon Pharmaceuticals' score of 0.46 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innoviva has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.88	$271.17M	$6.01	3.60
Lexicon Pharmaceuticals	$49.80M	19.58	-$50.34M	-$0.07	N/A

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Innoviva has a net margin of 119.89% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Innoviva's return on equity of 33.33% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Innoviva has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Innoviva presently has a consensus price target of $36.20, suggesting a potential upside of 67.32%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 107.29%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Innoviva beats Lexicon Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

53.0% of Novavax shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 1.0% of Novavax shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Novavax had 13 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 18 mentions for Novavax and 5 mentions for Lexicon Pharmaceuticals. Novavax's average media sentiment score of 0.61 beat Lexicon Pharmaceuticals' score of 0.46 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novavax has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.62	$440.30M	-$0.58	N/A
Lexicon Pharmaceuticals	$49.80M	19.58	-$50.34M	-$0.07	N/A

Novavax presently has a consensus price target of $12.13, indicating a potential upside of 9.34%. Lexicon Pharmaceuticals has a consensus price target of $4.55, indicating a potential upside of 107.29%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Novavax has a net margin of -14.73% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Novavax's return on equity of -14.82% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Novavax has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Summary

Novavax beats Lexicon Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 5 mentions for Lexicon Pharmaceuticals and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.62 beat Lexicon Pharmaceuticals' score of 0.46 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zenas BioPharma presently has a consensus target price of $44.29, suggesting a potential upside of 134.02%. Lexicon Pharmaceuticals has a consensus target price of $4.55, suggesting a potential upside of 107.29%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Zenas BioPharma is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lexicon Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	119.47	-$377.74M	-$8.47	N/A
Lexicon Pharmaceuticals	$49.80M	19.58	-$50.34M	-$0.07	N/A

Zenas BioPharma has a beta of -0.61, suggesting that its share price is 161% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Zenas BioPharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Summary

Zenas BioPharma and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXRX vs. The Competition

Export

Metric	Lexicon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$975.02M	$3.40B	$6.42B	$12.60B
Dividend Yield	N/A	2.28%	2.75%	5.26%
P/E Ratio	-31.35	18.93	21.28	26.32
Price / Sales	19.58	333.54	558.91	114.49
Price / Cash	N/A	125.26	43.49	56.90
Price / Book	4.77	7.29	10.60	7.34
Net Income	-$50.34M	$24.20M	$3.56B	$337.06M
7 Day Performance	1.62%	4.37%	3.21%	3.67%
1 Month Performance	41.61%	9.71%	6.51%	7.41%
1 Year Performance	232.68%	63.73%	36.74%	37.93%

Lexicon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXRX Lexicon Pharmaceuticals	1.9889 of 5 stars	$2.20 -0.7%	$4.55 +107.3%	+216.0%	$975.02M	$49.80M	N/A	140
CLDX Celldex Therapeutics	2.7486 of 5 stars	$30.73 flat	$49.78 +62.0%	+69.9%	$2.41B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	3.1344 of 5 stars	$8.29 flat	$20.70 +149.7%	-13.8%	$2.11B	$874.84M	N/A	530
INVA Innoviva	3.6434 of 5 stars	$22.46 flat	$36.20 +61.2%	+14.5%	$1.66B	$411.33M	3.74	100	Analyst Forecast
NVAX Novavax	1.834 of 5 stars	$9.21 flat	$12.13 +31.7%	+49.1%	$1.51B	$1.12B	N/A	1,990	Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXRX) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Lexicon Pharmaceuticals compare to Innoviva?

Summary

How does Lexicon Pharmaceuticals compare to Novavax?

Summary

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Do insiders & institutionals believe in LXRX or CLDX?

Do analysts rate LXRX or CLDX?

Which has higher valuation and earnings, LXRX or CLDX?

Does the media prefer LXRX or CLDX?

Is LXRX or CLDX more profitable?

Which has more volatility and risk, LXRX or CLDX?

Summary

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Is BCRX or LXRX more profitable?

Which has higher earnings and valuation, BCRX or LXRX?

Do institutionals & insiders have more ownership in BCRX or LXRX?

Does the media refer more to BCRX or LXRX?

Do analysts rate BCRX or LXRX?

Which has more volatility & risk, BCRX or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Innoviva?

Does the media refer more to INVA or LXRX?

Which has better earnings and valuation, INVA or LXRX?

Do insiders & institutionals hold more shares of INVA or LXRX?

Is INVA or LXRX more profitable?

Which has more risk & volatility, INVA or LXRX?

Do analysts prefer INVA or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Novavax?

Do insiders and institutionals have more ownership in NVAX or LXRX?

Does the media favor NVAX or LXRX?

Which has higher valuation and earnings, NVAX or LXRX?

Do analysts rate NVAX or LXRX?

Is NVAX or LXRX more profitable?

Which has more risk & volatility, NVAX or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Do institutionals & insiders hold more shares of ZBIO or LXRX?

Does the media favor ZBIO or LXRX?

Do analysts recommend ZBIO or LXRX?

Which has preferable earnings and valuation, ZBIO or LXRX?

Which has more volatility & risk, ZBIO or LXRX?

Is ZBIO or LXRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools